Siegels D, Heratizadeh A, Abraham S, et al. - By analyzing relevant randomized controlled trials (RCTs), researchers assessed systemic treatments for atopic dermatitis (AD) in terms of safety and efficacy. The included studies were systematically identified up to February 2020. Clinical signs, AD symptoms and health‐related quality of life were the primary efficacy outcomes. Experts examined 50 RCTs comprising 6,681 patients. The systemic treatments for which trial evidence was identified included apremilast, azathioprine (AZA), baricitinib, ciclosporin A (CSA), corticosteroids, dupilumab, interferon‐gamma, intravenous immunoglobulins, mepolizumab, methotrexate, omalizumab, upadacitinib and ustekinumab. They found the most robust, replicated high‐quality trial evidence supporting dupilumab’s efficacy and safety for up to 1 year in adults. In addition, for AZA, baricitinib and CSA, robust trial evidence was further identified. For all other systemic treatments, limited evidence‐based conclusions resulted from methodological restrictions. To ascertain the future role of conventional therapies, head‐to‐head trials with novel systemic treatments are needed.